Your browser doesn't support javascript.
loading
Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials.
Haney, Margaret; Vallée, Monique; Fabre, Sandy; Collins Reed, Stephanie; Zanese, Marion; Campistron, Ghislaine; Arout, Caroline A; Foltin, Richard W; Cooper, Ziva D; Kearney-Ramos, Tonisha; Metna, Mathilde; Justinova, Zuzana; Schindler, Charles; Hebert-Chatelain, Etienne; Bellocchio, Luigi; Cathala, Adeline; Bari, Andrea; Serrat, Roman; Finlay, David B; Caraci, Filippo; Redon, Bastien; Martín-García, Elena; Busquets-Garcia, Arnau; Matias, Isabelle; Levin, Frances R; Felpin, François-Xavier; Simon, Nicolas; Cota, Daniela; Spampinato, Umberto; Maldonado, Rafael; Shaham, Yavin; Glass, Michelle; Thomsen, Lars Lykke; Mengel, Helle; Marsicano, Giovanni; Monlezun, Stéphanie; Revest, Jean-Michel; Piazza, Pier Vincenzo.
Afiliación
  • Haney M; Department of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, NY, USA.
  • Vallée M; University of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.
  • Fabre S; Aelis Farma, Bordeaux, France.
  • Collins Reed S; Department of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, NY, USA.
  • Zanese M; Aelis Farma, Bordeaux, France.
  • Campistron G; Aelis Farma, Bordeaux, France.
  • Arout CA; Department of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, NY, USA.
  • Foltin RW; Department of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, NY, USA.
  • Cooper ZD; Department of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, NY, USA.
  • Kearney-Ramos T; University of California, Los Angeles, Los Angeles, CA, USA.
  • Metna M; Department of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, NY, USA.
  • Justinova Z; Aelis Farma, Bordeaux, France.
  • Schindler C; Behavioral Neuroscience Research Branch, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, MD, USA.
  • Hebert-Chatelain E; Behavioral Neuroscience Research Branch, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, MD, USA.
  • Bellocchio L; Department of Biology, University of Moncton, Moncton, NB, Canada.
  • Cathala A; University of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.
  • Bari A; University of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.
  • Serrat R; Aelis Farma, Bordeaux, France.
  • Finlay DB; Aelis Farma, Bordeaux, France.
  • Caraci F; Department of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
  • Redon B; University of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.
  • Martín-García E; Department of Drug and Health Sciences, University of Catania, Italy, and Oasi Research Institute-IRCCS, Unit of Translational Neuropharmacology, Troina, Italy.
  • Busquets-Garcia A; University of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.
  • Matias I; Basic Neuroscience Department, Université de Genève, Genève, Switzerland.
  • Levin FR; Laboratory of Neuropharmacology, Department of Medicine and Life Sciences, University Pompeu Fabra, Barcelona, Spain.
  • Felpin FX; University of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.
  • Simon N; Cell-Type Mechanisms in Normal and Pathological Behavior Research Group, Neuroscience Programme, IMIM Hospital del Mar Medical Research Institute, Barcelona, Spain.
  • Cota D; University of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.
  • Spampinato U; Department of Psychiatry, Columbia University Irving Medical Center, New York State Psychiatric Institute, New York, NY, USA.
  • Maldonado R; Nantes Université, CNRS, CEISAM, UMR 6230, Nantes, France.
  • Shaham Y; Aix Marseille Univ, APHM, INSERM, IRD, SESSTIM, Hop Sainte Marguerite, Service de Pharmacologie Clinique, Marseille, France.
  • Glass M; University of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.
  • Thomsen LL; University of Bordeaux, INSERM, Neurocentre Magendie, Bordeaux, France.
  • Mengel H; Laboratory of Neuropharmacology, Department of Medicine and Life Sciences, University Pompeu Fabra, Barcelona, Spain.
  • Marsicano G; Behavioral Neuroscience Research Branch, National Institute on Drug Abuse Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, MD, USA.
  • Monlezun S; Department of Pharmacology and Toxicology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.
  • Revest JM; Aelis Farma, Bordeaux, France.
  • Piazza PV; Aelis Farma, Bordeaux, France.
Nat Med ; 29(6): 1487-1499, 2023 Jun.
Article en En | MEDLINE | ID: mdl-37291212
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome de Abstinencia a Sustancias / Cannabis / Abuso de Marihuana / Alucinógenos Límite: Animals Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndrome de Abstinencia a Sustancias / Cannabis / Abuso de Marihuana / Alucinógenos Límite: Animals Idioma: En Revista: Nat Med Asunto de la revista: BIOLOGIA MOLECULAR / MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos